AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01891227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine will be dosed at 1000mg/m2 twice daily for 14 days, followed by a 7-day rest period for a total cycle time of 21 days (until disease progression or unacceptable toxic effects).
Study NCT01891227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine 80mg/m2 will be administered on day 1 and 8 of a three week cycle (for a maximum of eight cycles).
Study NCT02300194 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topic Morphine
Description: Topical application of a 0.1% morphine gel in patients undergo a procedure. It will be applied 30 minutes before the procedure and the first day every 4 hours. General basic sedation and systemic analgesia will give for all the patients. Efficacy of treatment will be measured with FLACC scale.
Study NCT02300194 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical application of a placebo hydrogel in patients undergo a procedure. It will be applied 30 minutes before the procedure and the first day every 4 hours. General basic sedation and systemic analgesia will give for all the patients. Efficacy of treatment will be measured with FLACC scale.
Study NCT03075826 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: SGI-110
Description: subcutaneously at a dose of 60 mg/m2
Study NCT03611595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib will be given orally once every day with cycles repeated every 4 weeks (28 days, +/- 3 days), with no rest periods between cycles
Study NCT03611595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 13-cis-retinoic acid
Description: 13-cis-retinoic acid at 80mg/m2/dose twice daily for two consecutive weeks (14 days) out of every four weeks (28 days, +/- 3 days).
Study NCT00122954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fish oil concentrate
Description: fish oil concentrate at a daily dose of 6 grams (2.1 gram EPA and 1.5 gram DHA).
Study NCT00122954 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: soybean oil with 1% fish oil at a daily dose of 6 grams
Study NCT05310266 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus abdominis plane block
Description: The investigators performed transversus abdominis plane block to that patient group for postoperative analgesia
Study NCT00457249 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADACEL®: Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed
Description: 0.5 mL, IM
Study NCT00457249 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DECAVAC®: Tetanus and Diphtheria Toxoids Adsorbed
Description: 0.5 mL, IM
Study NCT00062075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: romidepsin
Description: Given IV
Study NCT04424732 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Stereotactic Body Radiotherapy
Description: This is a prospective study of breast bone only oligometastases (up to three sites). Following systemic treatment and primary tumor control, patients will receive SBRT to all metastatic sites. Data on toxicities and oncological outcomes will be collected for future analysis. There will be no change in the standard systemic therapy nor the local therapy of the primary tumor.
Study NCT05310266 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus Lumborum Block
Description: The investigators performed quadratus lumborum block to that patient group for postoperative analgesia
Study NCT02358746 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: combined endo/epicardial approach
Study NCT02358746 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: stepwise approach
Description: endocardial scar homogenization only at the first VT ablation procedure
Study NCT01831310 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard (Kabiven)
Description: Parenteral nutrition provided 25-30 kcal/kg/day energy and 0.15-0.20 g/kg/day nitrogen. All nutrient substrates were mixed in 3 litre bags and infused in 24 h through a dedicated central venous line
Study NCT01371604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDX184
Description: IDX184 50 mg tablet administered orally
Study NCT01371604 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a (Peg-IFN)
Description: Peginterferon alfa-2 180 microgram prefilled syringe administered subcutaneously once weekly
Study NCT01371604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Ribavirin 200 mg tablets administered orally as a divided dose twice daily. Total daily dose to administered will be 1000 or 1200 mg based on body weight.
Study NCT01831310 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standard-Glutamine
Description: Parenteral nutrition (Kabiven) provided 25-30 kcal/kg/day energy and 0.15-0.20 g/kg/day nitrogen. it was 0.3-0.4 g/kg/day for glutamine dipeptide (Dipeptiven) supplementation. All nutrient substrates were mixed in 3 litre bags and infused in 24 h through a dedicated central venous line
Study NCT01831310 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standard-Omega 3 fatty acid
Description: Parenteral nutrition (Kabiven) provided 25-30 kcal/kg/day energy and 0.15-0.20 g/kg/day nitrogen. The dose of omega 3 fatty acid (omegaven)supplementation was 0.1-0.2 g/kg /day. All nutrient substrates were mixed in 3 litre bags and infused in 24 h through a dedicated central venous line
Study NCT01831310 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standard-glutamine-omega 3
Description: Parenteral nutrition (kabiven) provided 25-30 kcal/kg/day energy and 0.15-0.20 g/kg/day nitrogen. The dose of omega 3 fatty acid (omegaven) supplementation was 0.1-0.2 g/kg /day and it was 0.3-0.4 g/kg/day for glutamine dipeptide (dipeptiven)supplementation. All nutrient substrates were mixed in 3 litre bags and infused in 24 h through a dedicated central venous line
Study NCT03357458 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Integrated Care
Description: FICare is a dynamic psycho-educational intervention. The goal of FICare is a change in culture and practice that permits, encourages and supports parents in their parenting role while their infant is receiving health care in a Level II NICU. Underpinned by adult learning and change theories, FICare empowers parents to build their knowledge, skill and confidence so that the family is well-prepared to care for their infant long before discharge.
Study NCT00215826 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alferon LDO
Study NCT01479621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fp MDPI
Description: Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to 12.5, 25, 50 or 100 mcg of Fp one inhalation twice a day for a total daily dose of 25, 50, 100 or 200 mcg. Study drug was administered in the morning and in the evening
Study NCT01479621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flovent Diskus
Description: Flovent Diskus contains the active ingredient fluticasone propionate (Fp). Flovent Diskus 100 mcg was used twice a day, once in the morning and evening, for a total daily dose of 200 mcg of Fp. This therapy was not blinded as the inhaler device was different than the MDPI used in the other treatment arms.
Study NCT01479621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albuterol/salbutamol
Description: A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).
Study NCT01479621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo MDPI
Description: Placebo multidose dry powder inhaler in the morning and evening. Placebo MDPI was provided in devices identical in appearance to Fp MDPI.
Study NCT02353481 — intervention group
Intervention type: OTHER
Intervention: Heart Failure Management
Study NCT04607408 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CH505TF gp120
Description: HIV-1 CH505 transmitted/founder virus Env gp120 immunogen
Study NCT04607408 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLA-SE adjuvant
Description: An oil-in-water stable emulsion (SE) containing the immunological adjuvant Glucopyranosyl Lipid A (GLA)
Study NCT04607408 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride for Injection, 0.9% USP
Study NCT01371604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to IDX184 50 mg tablet administered orally
Study NCT03975894 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Serial prophylactic exchange blood transfusion (SPEBT).
Description: Serial prophylactic exchange blood transfusion (SPEBT) will be given via automated apheresis technology. SPEBT will be carried out on the haematology day unit or on the antenatal day unit/ward in accordance with local policies in participating units. The procedure will be carried out using standard operating procedures, by the clinical or research nurse/midwife, haematology day unit staff or specialist sickle nursing staff. Venous access will be via peripheral access if possible or by femoral line access if not.~SPEBT will be commenced between 6 and 18+0 weeks gestation. It will be repeated at 6-10 weekly intervals aiming to maintain HbS% \<30%. It will continue throughout pregnancy and be stopped at the end of pregnancy.~Number of red cell units used per transfusion will depend on patient weight and pre-transfusion HbS%, but will usually be between 6 and 8 units of red cells on each occasion of exchange transfusion.
Study NCT03629262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Patients in this group receive patient-controlled intravenous analgesia for 1-3 days after surgery. The formula is a mixture of dexmedetomidine (1.25 ug/ml) and sufentanil (1.25 ug/ml), diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout interval of 8 minutes.
Study NCT03629262 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in this group receive patient-controlled intravenous analgesia for 1-3 days after surgery. The formula is a mixture of placebo and sufentanil (1.25 ug/m), diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout interval of 8 minutes.
Study NCT04110015 — intervention group
Intervention type: DEVICE
Intervention: virtual visual field
Description: Patients with identified conditions will be invited to do a virtual visual field test with virtual reality headsets.
Study NCT03449979 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: XCSITE100 Stimulator Sham
Description: The participant will receive up to one minute of tACS stimulation until the stimulation fades. Sham stimulation mimics the skin sensations a participant would experience during a tACS session.
Study NCT03449979 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XCSITE100 Stimulator tACS
Description: Transcranial alternating current stimulation (tACS) is a method of noninvasive brain stimulation in which weak electrical current are applied to the scalp in a sine wave pattern to induce cortical oscillations at the frequency at which they are applied.
Study NCT01363206 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)
Description: GM-CSF will be administered subcutaneously daily for 14 days in a dose of 125 µg/m2 beginning on D1 of each 21-day cycle for 8 cycles until month 6. Maintenance therapy will begin at month 6 and will consist 14 days of GM-CSF repeated every 3 months for up to 2 years or until disease progression, whichever occurs first.
Study NCT01363206 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Patients will be treated with 4 courses of ipilimumab administered every 3 weeks intravenously in a dose of 10 mg/kg, with appropriate stopping/de-escalation rules. Maintenance therapy will begin at month 6 and will consist of ipilimumab in the same dose administered at the end of cycle 4 repeated every 3 months for up to 2 years or until disease progression, whichever occurs first.
Study NCT03095378 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Periodontal plastic surgery aiming root coverage by palatal connective tissue graft. Root treatment with scaling and root planing
Study NCT03095378 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: citric acid plus tetracycline
Description: Periodontal plastic surgery aiming root coverage by palatal connective tissue graft. Root treatment with citric acid plus tetracycline
Study NCT03095378 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: antimicrobial photodynamic therapy
Description: Periodontal plastic surgery aiming root coverage by palatal connective tissue graft. Root treatment with antimicrobial photodynamic therapy
Study NCT02072889 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neck Angle
Description: Ultrasound guided measures of the neck of subjects undergoing cardiac surgery who need internal jugular vein cannulated
Study NCT01504178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: duloxetine
Description: administration during 28 days
Study NCT01504178 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo of duloxetine
Description: administration during 28 days
Study NCT01504178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: injection of apomorphine
Description: injection performed at D28
Study NCT01504178 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: injection of apomorphine
Description: injection performed at D28
Study NCT01504178 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: injection of placebo of apomorphine
Description: performed at D28
Study NCT00738140 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Prevention Program
Description: 12-lesson program which will cover diet, exercise, and behavior modification.
Study NCT01628159 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lutonix Drug Coated Balloon
Description: balloon angioplasty with a drug coated balloon
Study NCT02686307 — intervention group
Intervention type: PROCEDURE
Intervention: ICD Implant
Description: Implantation of an implantable cardioverter/defibrillator
Study NCT03877835 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Peripheral nerve blocks
Description: LSIB + SSNB
Study NCT00634036 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pioglitazone
Description: pioglitazone tablets: 30 mg/day for 2 weeks; then increased to 45 mg/day until week 12 (approximately 3 months)
Study NCT00634036 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo (inert tablet)
Study NCT06066268 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Critical limb ischemia: analysis of RNAs
Description: analysis of miRNA expression levels
Study NCT06066268 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Controls: analysis of RNAs
Description: analysis of miRNAs expression levels
Study NCT01504178 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: L-Dopa
Description: performed at D28
Study NCT01504178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: injection of placebo of L-Dopa
Description: performed at D28
Study NCT01504178 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: injection of placebo of L-Dopa
Description: performed at D28
Study NCT03366727 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: drug-coated balloon catheter （Orchid, Acotec）
Description: After predilation, using drug-coated balloon catheter to cover the whole treated segment
Study NCT03366727 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: plain balloon catheter (Admiral, medtronic)
Description: After predilation, using plain balloon catheter to cover the whole treated segment
Study NCT03177525 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social SUCCESS
Description: Social SUCCESS will run for 12 weeks, with up to 5 children with ASD per group. Parents will attend didactic group sessions focused on motivating children with ASD to initiate to peers (90 min weekly) and will attend a portion of the existing 90 min social group to practice applying these strategies with their children and peer volunteers. Parent training will utilize the manual Improving Socialization in Individuals with Autism.
Study NCT03177525 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Wait List
Description: Participants assigned to the Wait List will continue stable community treatments for 12 weeks and will be provided an intervention similar to Social SUCCESS upon completion of all post measures.
Study NCT03309137 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chlorhexidine flush
Description: 1. For patients randomized to the CHG-LockTM device, attach a attach a BD Posiflush ™ 0.9% Sodium Chloride (Na Cl) 10ml syringe and a CHG-Lock™ device for each IV line that is to be locked. Follow hospital approved protocol for flush, volumes and hand hygiene.~   After a Catheter has been locked, before re-accessing the catheter for further sampling or infusions, all fluid should be aspirated from the catheter to clear the device of CHG, Heparin and the like. This should also confirm patency of the device.~2. Discard the syringe and device in biohazard waste.~3. Blue Cap the IV as per routine practice.
Study NCT02088177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long-acting injectable naltrexone
Description: Vivitrol is a long-acting opioid antagonist which blocks opioid agonists from binding at opioid receptors. It be administered as described above.
Study NCT00795899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin / Cyclophosphamide in combination with Paclitaxel/Trastuzumab, followed by postoperative Trastuzumab
Description: Cycles 1-4 Epirubicin: 90 mg/m2, i.v. day 1 Cyclophosphamide: 600 mg/m2, i.v. day 1 Every 22d~Cycles 5-8 Paclitaxel: 175 mg/m2, i.v., 3h-infusion day 1 Trastuzumab: 8 mg/kg i.v. at day 0 of the 5th cycle and thereafter each 6 mg/kg i.v. day 1 in the cycles 6-8 Every 22d
Study NCT04259671 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: My Autism Passport (MAP) Application
Description: Families will be given the application to upload to their mobile device and will be provided information on how to use the App by the research team. MAP is a mobile alternative to the paper version, and offers additional benefits such as the ability to set reminders, see regional developmental service agencies and other resources on a map, and directs the caregiver to information so that they may further their understanding about how to support their child.
Study NCT03123744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib 125mg
Description: Palbociclib 125 mg is administered orally at a starting dose of 125 mg/day for three weeks followed by one week off. Study evaluations include physical exams, performance status, vital signs, laboratory blood tests, and radiographic or MRI imaging.
Study NCT01766076 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: atorvastatin, Lipitor®
Description: PBMC collected for immune activation assays using flowcytometry
Study NCT01766076 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: atorvastatin, Lipitor®
Description: PBMC collected for immune activation assays using flowcytometry
Study NCT02303977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Study NCT02303977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study NCT03010475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: Oral administration A total of three single doses.
Study NCT03010475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Oral administration. A total of three single doses.
Study NCT03010475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNAC
Description: Oral administration. A total of five single doses.
Study NCT03010475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Oral administration. Once daily.
Study NCT03500237 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Team-Guided ICBT
Description: An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) for persons with chronic conditions course will be delivered to participants. In addition to the online program, a guide from the Online Therapy Unit team will respond within one business day of the client's email. The team of guides consist of registered social workers, psychologists or supervised graduate students, with experience delivering ICBT. Amount of contact will be personalized to participants' needs.